Resverlogix Updates Annual and Special Shareholders Meeting

On May 28, 2024, Resverlogix Corp., a biotechnology company listed on the Toronto Stock Exchange under the ticker RVX, announced the rescheduling of its Annual and Special Meeting of Shareholders. Originally slated for June 27, 2024, the Meeting will now take place on July 31, 2024, beginning at 1:00 pm Mountain Time. Shareholders will receive a Notice of Meeting and Management Information Circular outlining the topics to be discussed, which will also be filed on SEDAR+.

Founded in 2001 and based in Calgary, Alberta, Resverlogix is a late-stage biotechnology company that specializes in epigenetics. The company's mission is to develop innovative therapies aimed at treating chronic diseases by regulating the expression of disease-causing genes. Their focus is on restoring altered biological functions to a healthier state, particularly for patients suffering from serious illnesses like cardiovascular disease.

One of the primary elements of Resverlogix's clinical program is the development of apabetalone, an epigenetic drug candidate. This potential treatment is being evaluated for its efficacy in addressing cardiovascular disease, related comorbidities, and conditions arising from COVID-19. In addition, Resverlogix has partnered with EVERSANA™, a leader in global life sciences commercial services, to expedite the commercialization of apabetalone in the United States and Canada. The partnership aims to address cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension.

Resverlogix’s shares are publicly traded on the Toronto Stock Exchange (TSX) under the symbol RVX. Following the formal part of the Annual and Special Meeting, the company will offer a corporate update presentation.

The company has issued a caution regarding forward-looking statements included in their announcement. These statements, which refer to future events, plans, or performance, are inherently subject to risks and uncertainties. This includes uncertainties related to the timing and outcomes of the Annual and Special Meeting and the potential effectiveness of apabetalone in treating various chronic diseases. Resverlogix advises that actual results may differ significantly from those projected in forward-looking statements. These statements are based on various assumptions and are subject to risks detailed in the company's Annual Information Form and latest Management Discussion and Analysis (MD&A), which are accessible through SEDAR+.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!